These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31232464)

  • 1. Molecular pathology of the luminal class of urothelial tumors.
    Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
    J Pathol; 2019 Nov; 249(3):308-318. PubMed ID: 31232464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward a molecular pathologic classification of urothelial carcinoma.
    Sjödahl G; Lövgren K; Lauss M; Patschan O; Gudjonsson S; Chebil G; Aine M; Eriksson P; Månsson W; Lindgren D; Fernö M; Liedberg F; Höglund M
    Am J Pathol; 2013 Sep; 183(3):681-91. PubMed ID: 23827819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Lund Molecular Taxonomy Applied to Non-Muscle-Invasive Urothelial Carcinoma.
    Marzouka NA; Eriksson P; Bernardo C; Hurst CD; Knowles MA; Sjödahl G; Liedberg F; Höglund M
    J Mol Diagn; 2022 Sep; 24(9):992-1008. PubMed ID: 35853574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical Assays for Bladder Cancer Molecular Subtyping: Optimizing Parsimony and Performance of Lund Taxonomy Classifiers.
    Hardy CSC; Ghaedi H; Slotman A; Sjödahl G; Gooding RJ; Berman DM; Jackson CL
    J Histochem Cytochem; 2022 May; 70(5):357-375. PubMed ID: 35437049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.
    Garczyk S; Bischoff F; Schneider U; Golz R; von Rundstedt FC; Knüchel R; Degener S
    Virchows Arch; 2021 Aug; 479(2):325-335. PubMed ID: 33650041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification.
    Sjödahl G; Eriksson P; Liedberg F; Höglund M
    J Pathol; 2017 May; 242(1):113-125. PubMed ID: 28195647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
    Eriksson P; Aine M; Veerla S; Liedberg F; Sjödahl G; Höglund M
    BMC Med Genomics; 2015 May; 8():25. PubMed ID: 26008846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic implications of a three-antibody molecular subtyping algorithm for non-muscle invasive bladder cancer.
    Jackson CL; Chen L; Hardy CS; Ren KY; Visram K; Bratti VF; Johnstone J; Sjödahl G; Siemens DR; Gooding RJ; Berman DM
    J Pathol Clin Res; 2022 Mar; 8(2):143-154. PubMed ID: 34697907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudoangiosarcomatous urothelial carcinoma of the urinary bladder.
    Paner GP; Cox RM; Richards K; Akki A; Gokden N; Lopez-Beltran A; Krausz T; McKenney JK; Steinberg GD
    Am J Surg Pathol; 2014 Sep; 38(9):1251-9. PubMed ID: 25133708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
    Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
    Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
    Patschan O; Sjödahl G; Chebil G; Lövgren K; Lauss M; Gudjonsson S; Kollberg P; Eriksson P; Aine M; Månsson W; Fernö M; Liedberg F; Höglund M
    Eur Urol; 2015 Nov; 68(5):824-32; discussion 835-6. PubMed ID: 25770486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice.
    Queipo FJ; Unamunzaga GM; Negro BF; Fuertes SG; Cortés MÁ; Tejedor EC; Mañas CMB; Ariño AB; Sjödahl G; Beorlegui C
    Virchows Arch; 2022 Aug; 481(2):191-200. PubMed ID: 35731280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort.
    Marzouka NA; Eriksson P; Rovira C; Liedberg F; Sjödahl G; Höglund M
    Sci Rep; 2018 Feb; 8(1):3737. PubMed ID: 29487377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathology of the non-luminal Ba/Sq-like and Sc/NE-like classes of urothelial tumours: An integrated immunohistochemical analysis.
    Bernardo C; Eriksson P; Marzouka NA; Liedberg F; Sjödahl G; Höglund M
    Hum Pathol; 2022 Apr; 122():11-24. PubMed ID: 35108518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder Tumor Subtype Commitment Occurs in Carcinoma
    Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
    Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression.
    Olkhov-Mitsel E; Hodgson A; Liu SK; Vesprini D; Xu B; Downes MR
    J Clin Pathol; 2022 Nov; 75(11):766-771. PubMed ID: 34103388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
    Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
    Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes.
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Chebil G; Eriksson P; Johansson I; Kollberg P; Lindh C; Lövgren K; Marzouka NA; Olsson H; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 May; 81(5):523-532. PubMed ID: 34782206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.